Santalum album cream - Santalis Healthcare

Drug Profile

Santalum album cream - Santalis Healthcare

Alternative Names: Albuterpenoid; East Indian sandalwood oil; EISO; SAN 007; VIR 003

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator ViroXis
  • Developer Santalis Healthcare Corporation; Santalis Pharmaceuticals
  • Class Anti-infectives; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Atopic dermatitis; Molluscum contagiosum
  • Phase I Human papillomavirus infections; Poxvirus infections

Most Recent Events

  • 09 Sep 2016 Santalis Pharmaceuticals has patent protection for santalum album cream in Japan
  • 25 Aug 2016 Santalis Pharmaceuticals plans a phase II trial for Atopic dermatitis in USA (NCT02871479)
  • 25 Jan 2016 ViroXis is now called Santalis Healthcare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top